University of North Carolina, Chapel Hill
unc.eduLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
1,351
Active
169
Phase 3
20
Total enrollment
1,067,150
Pipeline matrix
Showing 40 of 69 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Transdermal estradiol | — | — | — | — | — | 2 | |
| Normal Saline | — | — | 6 | ||||
| Micronized progesterone | — | — | — | — | 3 | ||
| Propranolol | — | — | — | — | 3 | ||
| Rifaximin 550 MG Oral Tablet [XIFAXAN] | — | — | — | — | — | 1 | |
| Bupivacaine-epinephrine | — | — | — | — | — | 1 | |
| Mirikizumab - Intravenous | — | — | — | — | — | 1 | |
| Mirikizumab - Subcutaneous | — | — | — | — | — | 1 | |
| Transdermal placebo patch | — | — | — | — | — | 1 | |
| Kurvelo | — | — | — | — | — | 1 | |
| Raclopride C11 | — | — | — | — | — | 1 | |
| Initiating daily oral PrEP during pregnancy | — | — | — | — | — | 1 | |
| Already using daily oral PrEP at the time of pregnancy diagnosis | — | — | — | — | — | 1 | |
| Initiating injectable PrEP during pregnancy | — | — | — | — | — | 1 | |
| Already using injectable PrEP (CAB-LA) at the time of pregnancy diagnosis | — | — | — | — | — | 1 | |
| Dupilumab | — | — | — | — | — | 1 | |
| Fibrinolytic once daily | — | — | — | — | — | 1 | |
| Fibrinolytic twice daily | — | — | — | — | — | 1 | |
| DNA degradation once daily | — | — | — | — | — | 1 | |
| DNA degradation twice daily | — | — | — | — | — | 1 | |
| 7% Hypertonic Saline via nebulization | — | — | — | — | — | 1 | |
| LAIV nasal vaccine is chosen as a model viral infection | — | — | — | — | — | 1 | |
| Progesterone | — | — | — | — | 4 | ||
| psilocybin | — | — | — | — | — | 1 | |
| Liposomal bupivacaine | — | — | — | — | — | 1 | |
| Bupivacaine Hydrochloride | — | — | — | — | — | 1 | |
| Ketorolac | — | — | — | — | — | 1 | |
| 18F-fluorofuranylnorprogesterone PET / MRI | — | — | — | — | — | 1 | |
| BXCL501 | — | — | — | — | — | 1 | |
| Finerenone Oral | — | — | — | — | — | 1 | |
| Cashew sublingual immunotherapy | — | — | — | — | — | 1 | |
| Sodium Citrate | — | — | — | — | — | 1 | |
| Cyclobenzaprine HCl | — | — | — | — | — | 1 | |
| Ketotifen | — | — | — | — | — | 1 | |
| Cromolyn Sodium | — | — | — | — | — | 1 | |
| Anifrolumab | — | — | — | — | — | 1 | |
| Upadacitinib 30mg Dose | — | — | — | — | — | 1 | |
| Intralipid, 20% Intravenous Emulsion | — | — | — | — | — | 1 | |
| Placebos | — | — | — | — | — | 1 | |
| Baricitinib 4 milligram Oral | — | — | — | — | — | 1 |
29 more active programs hidden
Next readouts
- 2025-12
- 2026-01-22
- 2026-04-09
- 2026-04-16
- 2026-05
- 2026-06
- 2026-06-01
- 2026-06-30
- 2026-07
- 2026-07
Top conditions
- HIV57
- Obesity54
- HIV Infections51
- Healthy28
- Depression26
- HIV Infection23
- Schizophrenia22
- Overweight21
Frequently asked questions about University of North Carolina, Chapel Hill
- How many clinical trials does University of North Carolina, Chapel Hill have on ClinicalTrials.gov?
- University of North Carolina, Chapel Hill is listed as the lead sponsor on 1,351 clinical trials in ClinicalTrials.gov, 169 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University of North Carolina, Chapel Hill's trials are in Phase 3?
- 20 of University of North Carolina, Chapel Hill's trials are in Phase 3, spread across 69 active drug programs.
- What therapeutic areas does University of North Carolina, Chapel Hill focus on?
- University of North Carolina, Chapel Hill's most-studied conditions on ClinicalTrials.gov are HIV, Obesity, HIV Infections, Healthy, Depression.
- When are University of North Carolina, Chapel Hill's next clinical trial readouts?
- University of North Carolina, Chapel Hill has 10 upcoming primary-completion readouts tracked here; the soonest is “Sodium Citrate in Smell Retraining for People With Post-COVID-19 Olfactory Dysfunction”, expected around 2025-12.